It has also become clear that ADAM17 is important in cancers mediated by mutations in KRAS, which are the most frequent oncogenic mutations in human cancers, particularly in lung, colorectal and pancreatic tumours (Khan et al., 2019). Here, ADAM17 is linked to cancer.